The DOI matches its Crossref record.
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
Abstract
512 Background: The joint efficacy analysis of NCCTG N9831 and NSABP B-31 demonstrated improved outcomes with the addition of trastuzumab (H) to doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) in women with surgically removed HER2- positive breast cancer (NEJM 2005). Following this report, patients randomized to AC→T and less than 6 months from completion of chemotherapy were eligible to receive H. We have updated the initial combined results of these two trials. Methods: Primary and secondary efficacy endpoint were disease free survival (DFS) and overall survival (OS). Cox modeling was performed. Hazard ratios are adjusted for nodal status, tumor size, T schedule, hormone receptor status, and trial (also age for OS). Results: Among the 3,969 women enrolled (ages: 22 to 80yrs), there have been 619 events (H group: 222, non-H: 397). First events were: recurrence (511), contralateral breast disease (18), other second primary cancers (48), and death without recurrence or second primary cancers (42). The median follow-up among the 3,711 women still alive is 2.9 years (range up to 6,4 years). The 4 yr DFS rate and 4 yr OS rate respectively were: 85.9% (95%CI: 84.0–87.8%) and 92.6% (95%CI: 91.2–94.2%) in H group and 73.1% (95%CI: 70.6–75.8%) and 89.4% (95%CI: 87.6–91.2%) in non- H group. Hazard ratio for adjuvant (H/non-H) was 0.49 (P<0.0001; 95%CI: 0.41–0.58) for DFS and 0.63 (P=0.0004; 95%CI: 0.49–0.81) for OS.The rates of a first event per 1,000 women/year during yrs 1–4 were: 26.7, 52.9, 49.6 and 23.2 for H and 42.3, 102.3, 107.6 and 61.5 for non-H. The impact of crossover on clinical outcome will be explored. Conclusions: With an increase in the median follow-up of 11 months and with 225 additional events, the demonstration of substantial improvement in outcomes with the addition of trastuzumab to chemotherapy persist. This improvement continues in spite of some degree of cross-over occurring after the initial results were reported.Updated data regarding crossover outcomes and H duration (as they relate to disease free survival) will be presented. [Table: see text]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 861
Self-citationKaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
Self-citationHER2: Biology, Detection, and Clinical Implications
Gutierrez, C., & Schiff, R. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0454-rar.1 · Cited by 652
Metadata
- Authors
- Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kauffman, P. A., & Wolmark, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-06-20
- Volume
- 25
- Issue
- 18_suppl
- Pages
- 512-512
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2233806202
- Cited by
- 218
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. https://app.cochat.ai/papers/10.1200/jco.2007.25.18_suppl.512
- The paper
- Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kauffman, P. A., & Wolmark, N. (2007). Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.25.18_suppl.512
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.